SUPN
$50.82
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated fo...
Recent News
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, marking a 17.1% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally?
If you are wondering whether Supernus Pharmaceuticals at around US$55 a share offers good value or not, you are not alone. That is exactly what this article is here to unpack. The stock has returned 8.7% over the last 7 days, 14.4% over the last 30 days, 11.4% year to date and 73.6% over the past year, with a 5 year return of 116.0%. This naturally raises questions about how the current price stacks up against underlying value and risk. Recent attention on Supernus has been shaped by company...
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Supernus Pharmaceuticals, Inc.'s Q4 2025 earnings call
Supernus Pharmaceuticals Q4 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported fourth-quarter and full-year 2025 results on Monday, highlighting record revenue, expanding contributions from its “growth products,” and progress integrating Sage Therapeutics, including the addition of Zurzuvae collaboration revenue. Management also
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Supernus Pharmaceuticals Inc (SUPN) reports a 27% revenue increase and strategic expansion, despite facing supply constraints and increased expenses.